Home › Research › Treatments
The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect
Andrews D, Ducharme S, Chertkow H, Sormani MP, Collins DL, Alzheimer's Disease Neuroimaging Initiative.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025-01-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Introduction The phase 3 trial CLARITY AD found lecanemab slowed cognitive decline by 27%. However, subgroup analyses indicated a significant 31% sex difference in the effect and suggested no or limited effectiveness in females. We used simulations constrained by the trial design to determine whether that difference reflects a pre-existing sex difference in Alzheimer's disease progression or was a random event. Methods Simulations were generated using linear mixed models of cognitive decline fit to data from Alzheimer's Disease Neuroimaging Initiative participants satisfying CLARITY AD inclusion criteria. Results The statistically non-significant 7.9% smaller cognitive decline rate in our cohort's males versus females does not explain CLARITY AD's 31% sex difference in lecanemab's effect. A ≥ 31% difference occurred randomly in only 12 of our 10,000 simulations (0.0012 probability). Discussion CLARITY AD's sex difference was probably not random. Lecanemab is likely less effective in females than males, but we cannot conclude the drug is ineffective in females. Highlights Lecanemab is more clinically effective in males than in females. Forest plots should only report subgroup-specific effects in well-powered subgroups. Trial simulations based on real data enable investigation of subgroup drug effects. We cannot conclude that lecanemab is clinically ineffective in females. A sex difference in lecanemab's efficacy could be linked to its action mechanism.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Andrews, D., Ducharme, S., Chertkow, H., Sormani, M. P., Collins, D. L., & Alzheimer's Disease Neuroimaging Initiative. (2025). The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.14467
Vancouver
Andrews D, Ducharme S, Chertkow H, Sormani MP, Collins DL, Alzheimer's Disease Neuroimaging Initiative. The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. doi:10.1002/alz.14467. PMID: 39887549.
BibTeX
@article{andrews2025-39887549,
author = {Andrews, D. and Ducharme, S. and Chertkow, H. and Sormani, M. P. and Collins, D. L. and {Alzheimer's Disease Neuroimaging Initiative}},
title = {{The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2025},
doi = {10.1002/alz.14467},
pmid = {39887549},
url = {https://doi.org/10.1002/alz.14467}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- However, subgroup analyses indicated a significant 31% sex difference in the effect and suggested no or limited effectiveness in females.
- Results The statistically non-significant 7.9% smaller cognitive decline rate in our cohort's males versus females does not explain CLARITY AD's 31% sex difference in lecanemab's effect.
- Lecanemab is likely less effective in females than males, but we cannot conclude the drug is ineffective in females.
- We cannot conclude that lecanemab is clinically ineffective in females.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Effect size7.9%
- Evidence strengthModerate
How this study scored 55/100
Published in a leading specialty journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 32 of the 58 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39887549) |
| Free to read | 2 / 2 | Free to read |
| Points | 32 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 32 of the 58 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “higher”
2 studies in the library carry the topic tag “higher”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.